Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18

被引:308
作者
Pastrana, DV
Buck, CB
Pang, YYS
Thompson, CD
Castle, PE
FitzGerald, PC
Kjaer, SK
Lowy, DR
Schiller, JT
机构
[1] Natl Canc Inst, Cellular Oncol Lab, Bethesda, MD 20842 USA
[2] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[3] NCI, Genome Anal Unit, Bethesda, MD 20892 USA
[4] Danish Canc Soc, Inst Canc Epidemiol, Dept Virus Hormones & Canc, Copenhagen, Denmark
关键词
papillomavirus; neutralization; vector; vaccine; scrology; antibodies; HPV; virion; pseudovirus; virus-like particles;
D O I
10.1016/j.virol.2003.12.027
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter gene, were developed and validated for human papillornavirus (HPV)16, HPV18, and bovine papillomavirus 1 (BPV1). SEAP pseudoviruses were produced by transient transfection of codon-modified papillornavirus structural genes into an SV40 T antigen expressing line derived from 293 cells, yielding sufficient pseudovirus from one flask for thousands of titrations. In a 96-well plate format, in this initial characterization, the assay was reproducible and appears to be as sensitive as, but more specific than, a standard papillornavirus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA). The neutralization assay detected type-specific HPV16 or HPV18 neutralizing antibodies (titers of 160-10240) in sera of the majority of a group of women infected with the corresponding HPV type, but not in virgin women. Sera from HPV16 VLP vaccinees had high anti-HPV16 neutralizing titers (mean: 45000; range: 5120-163840), but no anti-HPV18 neutralizing activity. The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies. Published by Elsevier Inc.
引用
收藏
页码:205 / 216
页数:12
相关论文
共 60 条
  • [31] 2-6
  • [32] Immunity to oncogenic human papillomaviruses
    Konya, J
    Dillner, J
    [J]. ADVANCES IN CANCER RESEARCH, VOL 82, 2001, 82 : 205 - 238
  • [33] A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION
    KOUTSKY, LA
    HOLMES, KK
    CRITCHLOW, CW
    STEVENS, CE
    PAAVONEN, J
    BECKMANN, AM
    DEROUEN, TA
    GALLOWAY, DA
    VERNON, D
    KIVIAT, NB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) : 1272 - 1278
  • [34] A controlled trial of a human papillomavirus type 16 vaccine
    Koutsky, LA
    Ault, KA
    Wheeler, CM
    Brown, DR
    Barr, E
    Alvarez, FB
    Chiacchierini, LM
    Jansen, KU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) : 1645 - 1651
  • [35] Enhancement of capsid gene expression:: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes
    Leder, C
    Kleinschmidt, JA
    Wiethe, C
    Müller, M
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (19) : 9201 - 9209
  • [36] Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay
    Leiserowitz, GS
    Hall, KS
    Foster, CA
    Hitchcock, ME
    Christensen, ND
    Heim, K
    Smith, LH
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 66 (02) : 295 - 299
  • [37] Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity
    Liu, WJ
    Gao, FG
    Zhao, KN
    Zhao, WM
    Fernando, GJG
    Thomas, R
    Frazer, IH
    [J]. VIROLOGY, 2002, 301 (01) : 43 - 52
  • [38] LOWY DR, 2001, VIROLOGY, V2, P2231
  • [39] Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay 2
    Opalka, D
    Lachman, CE
    MacMullen, SA
    Jansen, KU
    Smith, JF
    Chirmule, N
    Esser, MT
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (01) : 108 - 115
  • [40] NHPV16VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
    Pastrana, DV
    Vass, WC
    Lowy, DR
    Schiller, JT
    [J]. VIROLOGY, 2001, 279 (01) : 361 - 369